Form 4: Cytosorbents Corp Director Edward Raymond Jones Reports Stock Option Grant

Director Edward Raymond Jones reports the acquisition of stock options in Cytosorbents Corp.

Summary

• On April 2, 2024, Edward Raymond Jones, a director of Cytosorbents Corp, was granted stock options to purchase 22,000 shares of common stock.
• The exercise price of these options is $0.955 per share.
• The options vest in four equal quarterly installments over one year, contingent upon continued service.
• The expiration date for these options is April 2, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates continued alignment of the director's interests with the company's performance.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of one year is fairly standard, encouraging continued service.
• Comparing the size of the grant to similar companies and director roles would provide further context on its significance.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholders by incentivizing the director to increase company value.
• The grant has a positive impact on the director, providing additional compensation and aligning their interests with the company's success.

Key Dates